Latest News

Immune checkpoint inhibitors (ICI) have become an integral part of the treatment of locally advanced or metastatic urothelial carcinoma (aUC).1–5 A significant minority of patients (about 15-20%) may achieve durable responses, but unfortunately, this remains the case in only this small subset of patients. Although increased tumor PD-L1 expression and the presence of a high tumor […]

The study design is unique since it includes all patients who completed 3 years follow-up after the last injection of the urethral bulking agent (UBA) Macroplastique®. While it is a strong design to offer the longitudinal, not cross-sectional, outcome it doesn’t include all ROSE study patients at the time of analysis, i.e., patients with less […]

INTRODUCTION Advances in novel treatment options may render renal cell cancer (RCC) patients susceptible to the financial toxicity (FT) of cancer treatment, and the factors associated with FT are unknown.

To compare the feasibility and outcomes of renal mass biopsies (RMB) of anatomically complex versus non-complex renal masses. Our institutional renal tumor database was queried for patients who underwent RMB between 2005-2019 and with available nephrometry score.

This study assessed the feasibility of a phase II randomized controlled trial of high-intensity interval training (HIIT), resistance training (RT), and usual care (UC) in men with prostate cancer (PCa) on active surveillance (AS) and evaluated changes in clinically relevant outcomes.

To externally validate and compare the performance of the European Randomized Study of Screening for Prostate Cancer risk calculator 3/4 (ERSPC-RC3/4), the Prostate Biopsy Collaborative Group risk calculator (PBCG-RC) and the van Leeuwen model to determine which prediction model would perform the best in a contemporary Australian cohort undergoing transperineal (TP) biopsy.

Combining an immune checkpoint inhibitor with a tumor vaccine may modulate the immune system to leverage complementary mechanisms of action that lead to sustained T-cell activation and a potent prolonged immunotherapeutic response in metastatic castration resistant prostate cancer (mCRPC).

This study assessed the contrasting genomic profiles from the primary tumors (PTs), metastatic (MET) sites, and circulating tumor DNA (ctDNA) of patients with prostate cancer (PC). A total of 1294 PC tissue specimens and 2462 ctDNA specimens underwent hybrid capture-based comprehensive genomic profiling (CGP).

PSMA-PET has become the PET technique of choice to localise the site of biochemically recurrent prostate cancer (PCa). With hybrid PET/MRI, the advantages of MRI are added to molecular characteristic of PET.

To define the clinical and pathological patterns of urinary bladder carcinoma from the University Hospital of Nepal. This is a retrospective analytical study. Patients with bladder mass who underwent surgery over 1 year and who had data record were included in the study.